Authors: L. Holubec, jr. 1; J. Fínek 1; O. Topolčan 2; J. Bouda 3; Z. Rokyta 3 Authors‘ workplace: Onkologické a radioterapeutické oddělení FN, Plzeň, přednosta prim. MUDr. J. Fínek, Ph. D. 2ONM – úsek imunodiagnostiky FN, Plzeň, vedoucí prof. MUDr. O. Topolčan, Ph. D. 3Gynekologicko-porodnická klinika FN, Plzeň, přednosta doc. MUDr. Z. Rokyta, CSc. 1 Published in: Ceska Gynekol 2004; (3): 225-229 Category:
Aim of Study: The authors present the view of possible usage of tumour markers in epithelialovarian cancer, and they aim at their use in routine clinic practice.Type of Study: Review article.Setting: Oncology and Radio-Therapeutic Department, Faculty Hospital, Pilsen.Subject and Methods of the Study: Summary of data published in Czech and foreign professionalliterature.Conclusion: In case of epithelium tumours of ovaries, CA 125 is the tumour marker of the fi rst choice.For the reason of low sensitivity, it is not possible to use the tumor markers for screening andprimary diagnostics. Regarding prognoses, high pre-operational levels of CA 125 are consideredunfavourable. At the same time the study demonstrates that CA 125 levels monitoring in the courseof chemotherapy appears to be one of the most signifi cant indicators of chemotherapy effects and,therefore, also of prognoses. Regular CA 125 monitoring in the course of follow up can contributeto early detection of tumour disease relapses. The optimal time interval for monitoring seems to bethree months for the period of the fi rst two years, and then six-month interval. Other tumour markersused in routine clinic practice are mainly CA 19-9 and CA 72-4, particularly in case of mucinoidepithelium tumours. However, these markers are of subsidiary importance only.
Key words: epithelial ovarian cancer, tumor markers, CA 125
Don‘t have an account? Create new account
Enter the email address that you registered with. We will send you instructions on how to set a new password.
